New observational evidence from a large US cohort suggests that, for men with metastatic castration-resistant prostate cancer (mCRPC) who previously received docetaxel and did not experience disease progression, re-exposure to docetaxel (“docetaxel rechallenge”) is associated with longer overall survival than treatment with cabazitaxel.
The retrospective cohort study analysed data from 669 patients within the nationwide Veterans Affairs health care system who were diagnosed with chemonaive mCRPC between 2010 and 2023 and received initial docetaxel. Eligible patients subsequently received either docetaxel rechallenge (n = 262) or cabazitaxel (n = 407) as their second taxane. The primary outcome was overall survival (OS) from the start of the second course of taxane therapy.
CLINICAL SUMMARY
What was examined
A real-world comparison of docetaxel rechallenge versus cabazitaxel as second taxane therapy in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
Key findings
- Docetaxel rechallenge was associated with longer overall survival than cabazitaxel (median 12.3 vs 9.6 months).
- Survival benefit remained significant after adjustment for clinical and demographic factors.
- PSA responses and time to next systemic treatment also favoured docetaxel rechallenge.
Clinical implications
- Docetaxel rechallenge may be a reasonable option for selected patients who previously tolerated and benefited from docetaxel.
- Findings are observational and should be interpreted in the context of patient selection and clinical judgement.
In weighted analyses accounting for demographic and clinical characteristics, median OS was longer with docetaxel rechallenge (12.3 months; interquartile range [IQR], 10.5–13.8) compared with cabazitaxel (9.6 months; IQR, 8.6–11.1). The hazard ratio for death with rechallenge versus cabazitaxel was 0.81 (95 % CI, 0.55–0.99; P = .04), indicating a statistically significant survival advantage in this cohort.
Secondary analyses were consistent with the primary finding, including prostate-specific antigen response and time to next systemic treatment or death, both of which favoured docetaxel rechallenge. For example, a reduction in prostate-specific antigen level of 90 % or more occurred in a greater proportion of patients in the docetaxel rechallenge group compared with cabazitaxel.
HER2 Uncovered: From Low to Ultralow – Get the Low Down with Ben Dessauvagie & Gelareh Farshid
The authors note that cabazitaxel has been an established option for patients previously treated with docetaxel, but the optimal sequencing of taxane chemotherapy in mCRPC remains uncertain. Docetaxel rechallenge is increasingly considered in clinical practice, particularly for patients who discontinued docetaxel for reasons other than disease progression, such as toxicity management or treatment breaks, although prospective randomised data comparing these approaches are limited.
Importantly, these findings arise from routine clinical care within a large integrated system and reflect real-world treatment patterns. As such, selection bias and residual confounding cannot be excluded, and the results do not replace evidence from randomised trials.
However, the observed association between docetaxel rechallenge and improved survival supports its consideration as a viable treatment option for carefully selected patients with mCRPC who previously tolerated and benefited from initial docetaxel.
Paper: Barata PC, Corrigan JK, La J, et al. Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Netw Open. 2026;9(1):e2551231. Access online here.
